Table 3.
Response and Survival by Use of ESAs
| Stage | Use of ESAs | No. | % MCyR | % CCyR | EFS, % at 7 Years (95% CI) | OS, % at 7 Years (95% CI) |
|---|---|---|---|---|---|---|
| All Patients (N=608) | ||||||
| ECP | Yes | 109 | 92a | 91a | 77 (67–87) | 90 (84–97) |
| No | 198 | 91b | 84b | 71 (64–78) | 87 (81–93) | |
| P | .88 | .09 | .30 | .87 | ||
| LCP | Yes | 108 | 76 | 69 | 60 (51–70) | 75 (66–83) |
| No | 193 | 79c | 72c | 62 (54–69) | 82 (76–88) | |
| P | .57 | .59 | .78 | .19 | ||
| Patients who received standard-dose imatinib only (n=359) | ||||||
| ECP | Yes | 24 | 75 | 71 | 60 (40–81) | 83 (68–98) |
| No | 75 | 88d | 78d | 70 (58–81) | 85 (76–94) | |
| P | .12 | .33 | .25 | .43 | ||
| LCP | Yes | 99 | 75 | 68 | 60 (50–70) | 75 (66–83) |
| No | 161 | 75e | 68e | 62 (53–70) | 80 (73–86) | |
| P | .89 | .96 | .76 | .49 | ||
ESA indicates erythropoietic-stimulating agent; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; EFS, event-free survival; CI, confidence interval; OS, overall survival; ECP, early chronic phase; LCP, late chronic phase.
a
From 108 evaluable patients.
b
From 193 evaluable patients.
c
From 188 evaluable patients.
d
From 72 evaluable patients.
e
From 159 evaluable patients.